Human normal immunoglobulin in the treatment of primary immunodeficiency diseases
Philip WoodSt James University Hospital, Leeds, United KingdomAbstract: The primary antibody deficiency syndromes are a rare group of disorders that can present at any age, and for which delay in diagnosis remains common. Replacement therapy with immunoglobulin in primary antibody deficiencies incre...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2012-04-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | http://www.dovepress.com/human-normal-immunoglobulin-in-the-treatment-of-primary-immunodeficien-a9613 |
| _version_ | 1818896674518466560 |
|---|---|
| author | Wood P |
| author_facet | Wood P |
| author_sort | Wood P |
| collection | DOAJ |
| description | Philip WoodSt James University Hospital, Leeds, United KingdomAbstract: The primary antibody deficiency syndromes are a rare group of disorders that can present at any age, and for which delay in diagnosis remains common. Replacement therapy with immunoglobulin in primary antibody deficiencies increases life expectancy and reduces the frequency and severity of infection. Higher doses of immunoglobulin are associated with reduced frequency of infection. Late diagnosis and delayed institution of immunoglobulin replacement therapy results in increased morbidity with a wide variety of organ-specific complications and increased mortality. Risks of immunoglobulin therapy are minimized by modern manufacturing processes, although patients can experience both immediate and delayed adverse reactions, and concerns remain over the transmission of prions in plasma. Immunoglobulin therapy leads to improvements in overall quality of life, and many of the improvements relate to reduced infection rates and fear of future infections, strongly suggesting that the immunoglobulin therapy itself is the major factor in this improvement. There are limited data on the economic benefits of immunoglobulin therapy, with the fluctuating costs of immunoglobulins making comparison between different studies difficult. However, estimates suggest that early intervention with immunoglobulin replacement compares favorably with prolonged therapy for other more common chronic diseases.Keywords: antibody deficiency, immunoglobulin therapy, common variable immunodeficiency |
| first_indexed | 2024-12-19T19:04:02Z |
| format | Article |
| id | doaj.art-5b7521401f944f8286e87bb45488c9d6 |
| institution | Directory Open Access Journal |
| issn | 1176-6336 1178-203X |
| language | English |
| last_indexed | 2024-12-19T19:04:02Z |
| publishDate | 2012-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-5b7521401f944f8286e87bb45488c9d62022-12-21T20:09:30ZengDove Medical PressTherapeutics and Clinical Risk Management1176-63361178-203X2012-04-012012default157167Human normal immunoglobulin in the treatment of primary immunodeficiency diseasesWood PPhilip WoodSt James University Hospital, Leeds, United KingdomAbstract: The primary antibody deficiency syndromes are a rare group of disorders that can present at any age, and for which delay in diagnosis remains common. Replacement therapy with immunoglobulin in primary antibody deficiencies increases life expectancy and reduces the frequency and severity of infection. Higher doses of immunoglobulin are associated with reduced frequency of infection. Late diagnosis and delayed institution of immunoglobulin replacement therapy results in increased morbidity with a wide variety of organ-specific complications and increased mortality. Risks of immunoglobulin therapy are minimized by modern manufacturing processes, although patients can experience both immediate and delayed adverse reactions, and concerns remain over the transmission of prions in plasma. Immunoglobulin therapy leads to improvements in overall quality of life, and many of the improvements relate to reduced infection rates and fear of future infections, strongly suggesting that the immunoglobulin therapy itself is the major factor in this improvement. There are limited data on the economic benefits of immunoglobulin therapy, with the fluctuating costs of immunoglobulins making comparison between different studies difficult. However, estimates suggest that early intervention with immunoglobulin replacement compares favorably with prolonged therapy for other more common chronic diseases.Keywords: antibody deficiency, immunoglobulin therapy, common variable immunodeficiencyhttp://www.dovepress.com/human-normal-immunoglobulin-in-the-treatment-of-primary-immunodeficien-a9613 |
| spellingShingle | Wood P Human normal immunoglobulin in the treatment of primary immunodeficiency diseases Therapeutics and Clinical Risk Management |
| title | Human normal immunoglobulin in the treatment of primary immunodeficiency diseases |
| title_full | Human normal immunoglobulin in the treatment of primary immunodeficiency diseases |
| title_fullStr | Human normal immunoglobulin in the treatment of primary immunodeficiency diseases |
| title_full_unstemmed | Human normal immunoglobulin in the treatment of primary immunodeficiency diseases |
| title_short | Human normal immunoglobulin in the treatment of primary immunodeficiency diseases |
| title_sort | human normal immunoglobulin in the treatment of primary immunodeficiency diseases |
| url | http://www.dovepress.com/human-normal-immunoglobulin-in-the-treatment-of-primary-immunodeficien-a9613 |
| work_keys_str_mv | AT woodp humannormalimmunoglobulininthetreatmentofprimaryimmunodeficiencydiseases |